January 26, 2022
Ono Pharmaceutical said on January 25 that its PD-1 inhibitor Opdivo (nivolumab) has won Taiwanese regulatory approval in combination with bevacizumab and chemotherapy for the frontline treatment of certain patients with non-squamous non-small cell lung cancer (NSCLC). The combo therapy...read more